Dr. Lisa Gennarini, MD
Claim this profileMontefiore Medical Center - Moses Campus
Expert in Cancer
Expert in Uterine Tumors
57 reported clinical trials
117 drugs studied
About Lisa Gennarini, MD
Education:
- Earned an MD (Doctor of Medicine).
Experience:
- Served as Principal Investigator for the Phase III clinical trial "A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor" at Montefiore Medical Center - Moses Campus.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Uterine Tumors
Global LeaderStage I
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Lisa Gennarini, MD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
More about Lisa Gennarini, MD
Clinical Trial Related5 years of experience running clinical trials · Led 57 trials as a Principal Investigator · 18 Active Clinical TrialsTreatments Lisa Gennarini, MD has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Nivolumab
- Vincristine
Breakdown of trials Lisa Gennarini, MD has run
Cancer
Uterine Tumors
T-Lymphoblastic Leukemia/Lymphoma
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lisa Gennarini, MD specialize in?
Lisa Gennarini, MD focuses on Cancer and Uterine Tumors. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Lisa Gennarini, MD currently recruiting for clinical trials?
Yes, Lisa Gennarini, MD is currently recruiting for 13 clinical trials in Bronx New York. If you're interested in participating, you should apply.
Are there any treatments that Lisa Gennarini, MD has studied deeply?
Yes, Lisa Gennarini, MD has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Lisa Gennarini, MD?
Apply for one of the trials that Lisa Gennarini, MD is conducting.
What is the office address of Lisa Gennarini, MD?
The office of Lisa Gennarini, MD is located at: Montefiore Medical Center - Moses Campus, Bronx, New York 10467 United States. This is the address for their practice at the Montefiore Medical Center - Moses Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.